First Joe Biden, Now Bill Gates: Tech Pioneer Overlooks Elon Musk’s Full Self-Driving, Praises Startup
The development of full self-driving technology may be at a point of contention between Elon Musk and Bill Gates.
‘Go Off The Beaten Track,’ Market Guru Says: Buy Growth Names
Tech stocks are poised for a strong year, with growth names looking particularly attractive, according to Marc Chaikin, founder and CEO of
Morgan Stanley: Schwab Is Vulnerable To A Bank Run, Forced To Sell Securities At A Loss
Analysts at Morgan Stanley downgraded Charles Schwab Corp (NYSE: SCHW) on Tuesday, citing concerns over cash sorting and regulatory changes.
Bristol Myers’ Flagship Opdivo Shows Long Term Durable Benefits In Lung Cancer Patients
Bristol Myers Squibb & Co (NYSE:BMY) announced three-year follow-up results from the Phase 3 CheckMate -816 trial of Opdivo (nivolumab) in…
GSK Bets On Scynexis’ FDA-Approved Antifungal Drug For Over $500M In Bio Bucks
GSK plc (NYSE:GSK) and Scynexis Inc (NASDAQ:SCYX) have entered into an exclusive license agreement for Brexafemme (ibrexafungerp tablets). The FDA approved the antifungal…
Apple Pay Later Vs. AAPL Pay Later: Which Is More Rewarding?
At the Worldwide Developers Conference last June, Apple Inc (NASDAQ: AAPL) announced its entry into the buy now, pay later market with the introduction of its Apple Pay Later program.
Viatris Among Three Companies Licensed To Make GSK/Pfizer-Backed Long Acting HIV Prevention Drug
ViiV Healthcare and Medicines Patent Pool (MPP) have signed sublicence agreements with Aurobindo Pharma, Cipla Limited, and Viatris Inc (NASDAQ:VTRS) – through its subsidiary Mylan – to…
Johnson & Johnson Pulls Plug On Large Late-Stage Study Of RSV Vaccine Candidate; GSK, Pfizer Shots Are Under FDA Review
After reviewing its portfolio to prioritize and assessing the respiratory syncytial virus (RSV) vaccine landscape, Janssen, a unit of Johnson…
AstraZeneca Axes Pneumonia Drug Pact With Aridis
AstraZeneca plc (NASDAQ: AZN) scrapped its license agreement with Aridis Pharmaceuticals Inc (NASDAQ: ARDS).